Bitte benutzen Sie diese Kennung, um auf die Ressource zu verweisen: http://doi.org/10.25358/openscience-220
Autoren: Juengel, Eva
Natsheh, Iyad
Najafi, Ramin
Rutz, Jochen
Tsaur, Igor
Haferkamp, Axel
Chun, Felix K.-H.
Blaheta, Roman A.
Titel: Mechanisms behind temsirolimus resistance causing reactivated growth and invasive behavior of bladder cancer cells in vitro
Online-Publikationsdatum: 8-Nov-2019
Erscheinungsdatum: 2019
Sprache des Dokuments: Englisch
Zusammenfassung/Abstract: Background: Although mechanistic target of rapamycin (mTOR) inhibitors, such as temsirolimus, show promise in treating bladder cancer, acquired resistance often hampers efficacy. This study evaluates mechanisms leading to resistance. Methods: Cell growth, proliferation, cell cycle phases, and cell cycle regulating proteins were compared in temsirolimus resistant (res) and sensitive (parental—par) RT112 and UMUC3 bladder cancer cells. To evaluate invasive behavior, adhesion to vascular endothelium or to immobilized extracellular matrix proteins and chemotactic activity were examined. Integrin α and β subtypes were analyzed and blocking was done to evaluate physiologic integrin relevance. Results: Growth of RT112res could no longer be restrained by temsirolimus and was even enhanced in UMUC3res, accompanied by accumulation in the S- and G2/M-phase. Proteins of the cdk-cyclin and Akt-mTOR axis increased, whereas p19, p27, p53, and p73 decreased in resistant cells treated with low-dosed temsirolimus. Chemotactic activity of RT112res/UMUC3res was elevated following temsirolimus re-exposure, along with significant integrin α2, α3, and β1 alterations. Blocking revealed a functional switch of the integrins, driving the resistant cells from being adhesive to being highly motile. Conclusion: Temsirolimus resistance is associated with reactivation of bladder cancer growth and invasive behavior. The α2, α3, and β1 integrins could be attractive treatment targets to hinder temsirolimus resistance.
DDC-Sachgruppe: 610 Medizin
610 Medical sciences
Veröffentlichende Institution: Johannes Gutenberg-Universität Mainz
Organisationseinheit: FB 04 Medizin
Veröffentlichungsort: Mainz
ROR: https://ror.org/023b0x485
DOI: http://doi.org/10.25358/openscience-220
Version: Published version
Publikationstyp: Zeitschriftenaufsatz
Nutzungsrechte: CC BY
Informationen zu den Nutzungsrechten: https://creativecommons.org/licenses/by/4.0/
Zeitschrift: Cancers
11
6
Seitenzahl oder Artikelnummer: Art. 777
Verlag: MDPI
Verlagsort: Basel
Erscheinungsdatum: 2019
ISSN: 2072-6694
URL der Originalveröffentlichung: http://dx.doi.org/10.3390/cancers11060777
DOI der Originalveröffentlichung: 10.3390/cancers11060777
Enthalten in den Sammlungen:JGU-Publikationen

Dateien zu dieser Ressource:
  Datei Beschreibung GrößeFormat
Miniaturbild
59403.pdf4.91 MBAdobe PDFÖffnen/Anzeigen